Development and characterization of cisplatin-resistant human testicular and bladder tumour cell lines.
Cisplatin-resistant cells were derived in vitro from a human bladder carcinoma cell line (RT112) and a testicular tumour cell line (SuSa) by continuous exposure to increasing concentrations of cisplatin for 14 and 11 months, respectively. Both resistant cell lines had a four-fold level of resistance relative to their parental cell lines, comparing the cisplatin concentration to inhibit colony forming ability by 70%. These levels of resistance were retained in the absence of cisplatin for at least 3 months. In each case, four-fold fewer micronuclei were produced in the resistant lines by the same cisplatin concentrations. Cross-resistance to carboplatin and methotrexate was observed in both resistant cell lines, but neither line was resistant to doxorubicin. Isozyme and DNA analysis with hypervariable probes confirmed the origin of each resistant cell line from its parental line. Population doubling times and intermitotic times were similar in each of the pairs of cell lines. Karyotyping showed that the resistant cell lines had gained and lost marker chromosomes, but there were no changes common to both resistant cell lines.
Walker
M C
MC
Cancer Research Campaign, London, U.K.
Povey
S
S
Parrington
J M
JM
Riddle
P N
PN
Knuechel
R
R
Masters
J R
JR
D002295:Carcinoma, Transitional Cell / Q000188:drug therapy; D002460:Cell Line; D002945:Cisplatin / Q000627:therapeutic use*; D004351:Drug Resistance; D006801:Humans; D008297:Male; D013724:Teratoma / Q000188:drug therapy; D013736:Testicular Neoplasms / Q000188:drug therapy*; D014407:Tumor Cells, Cultured / Q000187:drug effects*; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*
D002945:Cisplatin